Found a bug or want a feature? Verified reports earn free credits.
Log inSign up
NSE:BALAXI

BALAXI PHARMA LTD

₹22.16
at close · 8 Oct 2026
▼ 0.26 (-1.16%)

Latest filings

  1. Quarterly compliance certificate for dematerialization of shares filed · Compliance
  2. RTA Report on Re-Lodgement of Physical Share Transfer Requests - Sep 2026 · Compliance
  3. Newspaper ad on special window for physical share transfer and demat · Compliance
All filings ↓
Ask Nexa about BALAXI PHARMA LTD

Snapshot

What the business is, and whether it's a good one at a fair price.

AI · written from filings

Wholesale trades pharmaceutical products internationally, with 100% of revenue from exports across seven countries and a portfolio of 964 registered products. The company runs an asset-light model, sourcing 100% of products from GMP-certified CDMOs (Contract Development and Manufacturing Organisations), supported by 62 permanent employees. LATAM was a key geography, generating ₹111.29 crore with 11% year-on-year growth in FY26. The Angola institutional business faced extended working capital cycles that pulled consolidated revenue down 7.7% to ₹270.17 crore. The company is now adding backward integration: its Jadcherla formulation plant near Hyderabad received its Manufacturing Licence on May 23, 2026, with commercial production slated for Paracetamol 500mg and Piroxicam 20mg capsules, raw materials already stocked, and 40 additional product permissions applied for. WHO-GMP certification is being pursued. Materials (pharma products sourced from CDMOs) form the largest cost at 55.8% of revenue, followed by employee costs at 14.1% and other operating expenses at 26.9%.

Operating scale
Product portfolio
964 products across 7 countriesFY26
New product registrations in FY26
49
LATAM revenue
₹111.29 crore (11% YoY growth)FY26
Permanent employees
62
Jadcherla formulation plant
Manufacturing Licence received May 23, 2026; initial products Paracetamol 500mg and Piroxicam 20mg capsulesFY26
Additional product permissions applied
40
Who pays it
International wholesale buyers of pharmaceutical products across seven countries, including institutional buyers in Angola and LATAM
Biggest cost
Materials (pharma products sourced from GMP-certified CDMOs) at 55.8% of revenue
Kind of business
Asset-light international pharma wholesaler now adding backward integration into formulation manufacturing
Where it sits
100% export-oriented pharma wholesaler with 964 registered products across seven countries; adding first owned formulation plant at Jadcherla, Hyderabad
Market Cap
₹122 Cr
P / E (TTM)
49.2×
EV / EBITDA
12.9×
Div Yield
—
Growth
3.2%▲
Revenue 5y CAGR
PAT -48.2% · EBITDA -24.0%
Quality
3.1%·
ROCE (FY26)
ROE 0.6% · margin 4.2%
Leverage
0.22·
Debt / Equity · low
Net debt ₹41 Cr
Revenue FY21→FY26
1.2×▲
Margin −16.0 pts
₹231 Cr → ₹270 Cr
Cash conversion
0.05×▼
Operating cash ÷ profit · 5 yrs
₹6 Cr on ₹118 Cr
Moves on a normal day
1.49%·
Median daily move
Last 268 sessions · the yardstick for filing-day moves

Scorecard

Measured from the filed financials · as of FY26 — not investment advice

Strengths
Debt at 0.22× equity
Concerns
Slow revenue growth — 3% a year over 5 years
Profit shrinking over 5 years (−48% a year)
Erratic profits — up in only 2 of the last 5 years
Returns on capital 3.1%
Over 5 years it reported ₹118 Cr of profit and ₹5.58 Cr of operating cash — 0.05×
Less than 60p of every ₹1 of profit arrived as cash
Heavy working capital — 297 days of cash tied up
EPS grew slower than profit — the share count rose (bonus or dilution)

Charts

How has the market priced it — with filings on the timeline?

BALAXI · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Peers

How does it stack up on valuation, returns and growth?

Loading peers…

Financials

Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.

Loading financials…

Ownership

Who owns it — and is the promoter stake clean?

Loading shareholding…

Sign up to see the full company file

Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.

Common questions

Answered from BALAXI PHARMA LTD's filed financials and exchange disclosures

What does BALAXI PHARMA LTD do?

BALAXI PHARMA LTD is listed on NSE, trading under the symbol BALAXI.

Is BALAXI PHARMA LTD profitable?

Yes. Over the trailing twelve months BALAXI PHARMA LTD reported a net profit of ₹2.42 Cr on revenue of ₹280 Cr.

Does BALAXI PHARMA LTD pay a dividend?

Not in the latest reported year — BALAXI PHARMA LTD's dividend payout for FY26 was nil.

Is BALAXI PHARMA LTD debt-free?

No. It reported borrowings of ₹56 Cr on its 31 Mar 2026 balance sheet, or net debt of ₹41 Cr after cash. Debt stands at 0.22× equity.

How much does the BALAXI PHARMA LTD share price move in a day?

On a typical session BALAXI PHARMA LTD moves 1.49% — that is the median absolute close-to-close move across its last 268 trading days. MarketPing measures each filing's price reaction against it.

Where can I track BALAXI PHARMA LTD's announcements?

Every NSE and BSE filing by BALAXI PHARMA LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.

Figures are as last reported and may lag the latest filing. Not investment advice.